Navigation Links
Stenting a Good Option for Left Main Heart Artery
Date:8/19/2009

As effective as standard of bypass surgery, Polish study finds

WEDNESDAY, Aug. 19 (HealthDay News) -- Twelve-year data on treatment of blockage of the left main heart artery indicate that using a drug-coated stent is an effective alternative to bypass surgery, doctors report.

The study of 314 people who underwent the procedure between 1997 and 2008 in Poland supports the findings of a large European trial, which found no difference in the death rate between bypass surgery and angioplasty for the condition, according to a report published online Aug. 19 and in an upcoming print issue of the Journal of the American College of Cardiology by a group of physicians from Poland and the United States.

While no more than 5 percent of cases of coronary artery disease involve the left main artery, there has been controversy about the best treatment, in part because the vessel supplies blood to two-thirds of the heart muscle.

"In the earliest days, it was found that surgical revascularization [restoration of blood flow] prolonged survival," said Dr. David R. Holmes, the Scripps professor of medicine at the Mayo Graduate School of Medicine, and a participant in the earlier European trial.

While the left main vessel is an easy target for insertion of a balloon that is expanded to widen the artery, concerns that the procedure would not prevent the artery from closing again limited its use, Holmes said. But the arrival of stents -- thin metal tubes that help keep the artery open -- and then of stents coated with drugs to prevent clotting, made the procedure more feasible, he said.

The SYNTAX study, sponsored by stent maker Boston Scientific Inc. and reported last year, found no difference in the mortality rate between people who had angioplasty and stent implants, and those who had bypass surgery.

"It showed that selected patients with left main disease could be treated with drug-eluting stents," Holmes said.

The newly reported study helps show that "in some patients, not a majority, angioplasty is a very satisfactory alternative to bypass surgery," Holmes added.

"Long-term mortality of 13.9 percent at four years and the five- and 10-year survival of 78.1 percent and 68.9 percent are very satisfactory and compare favorably with survival presented in long-term outcomes of coronary artery bypass surgery," the report said.

At this time, the treatment of choice for left main artery disease depends largely on the country in which it is treated, Holmes said.

"In Japan or Korea, the treatment of choice is stenting," he said. "In the United States, the predominant treatment is coronary artery bypass surgery."

The results of the study in Poland might tip the scales slightly toward stenting, since it is a study "looking at real-life results," Holmes said. "The quality of evidence is not as good as in a randomized trial, but still is good."

But there is no hard-and-fast rule for making the choice, Holmes said. In some cases, "there is no good surgical option," he said. In other cases, the choice may be made by an individual's preference, since "some patients like to avoid open-heart surgery," Holmes said.

The study could influence medical practice in the United States, said Dr. Jeffrey W. Moses, a professor of medicine at Columbia University Medical Center, and co-author of an accompanying editorial.

"It gives a very long time perspective, now going out for multiple years, really indicating that the overall outcomes are pretty stable, especially if you look at mortality rates over time," Moses said.

A number of other studies have "said the same thing, that if the thing is done properly, in the right hands, it can be done safely with a good long-term outcome," Moses said. "This, along with the other studies, is going to move the consensus over a bit, at least widening the group of patients eligible to have stenting as a reasonable alternative to bypass surgery."

More information

You can learn about stenting from the American Heart Association.



SOURCES: David R. Holmes, M.D., Scripps professor of medicine, Mayo Graduate School of Medicine, Rochester, Minn.; Jeffrey W. Moses, professor, medicine, Columbia University Medical Center, New York City; Aug. 19, 2009, Journal of the American College of Cardiology, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
2. Is Bypass Truly Better than Stenting?
3. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
4. SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery
5. NEJM study demonstrates carotid stenting with embolic protection is comparable to surgery
6. Stenting as Good as Surgery for Stroke Prevention
7. Renal artery stenting falls short in large randomized trial
8. The Elderly Can Be Candidates for Angioplasty, Stenting
9. Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
10. Vascular surgeons ask, whats next for carotid artery stenting?
11. Research sheds light on carotid artery stenting risk in elderly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stenting a Good Option for Left Main Heart Artery 
(Date:7/20/2017)... ... ... ChenMed , a leading provider of value-based care for seniors, today announced ... Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine at the ... for the UVA Health System, brings 30 years of highly relevant experience to his ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced ... its existing adherence automation lines. The ATP® Mini and InspectRx® Mini ... TCG’s standard products, but at a size and price point that can help ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... International plc (NASDAQ: ENDP ) will announce its second-quarter ... senior management team will host a conference call and webcast before ... The dial-in number to access the call is U.S./ ... is 45397076. Please dial in 10 minutes prior to the scheduled ... of the call will be available from August 8, 2017 at ...
(Date:7/12/2017)... 2017 CarpalAID is a revolutionary new product that relieves ... Carpal tunnel syndrome affects more than 8 million people a ... of men. The common methods of treating CTS are painful surgery, ... braces or gloves. ... CarpalAID is a clear patch worn on the palm ...
(Date:7/11/2017)... , July 11, 2017  Sysmex America, Inc., ... diagnostic testing equipment as well as middleware information ... way to make quality assurance easier and more ... is well known for the innovation that it ... Monitor elevates quality assurance processes to a new ...
Breaking Medicine Technology: